Last Price$20.72.1%
Market Cap$972.8M
LTM Dividend per Share (DPS)
$0.0
5Y avg
$0.0
Biotechnology industry
median
$0.0
Stock quality & Intrinsic value
6/10
(0.3%) overvalued
Enliven Therapeutics, Inc. Dividend per Share (DPS)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
| Dividend per Share (DPS) | $0.0 | $0.0 | $0.0 | $0.0 |
Overvalued or undervalued?
Check the intrinsic value for ELVN
and see if it's the right time to invest.
Enliven Therapeutics, Inc. (ELVN) Dividend per Share (DPS) comparison analysis
General
LTM Dividend per Share (DPS)
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Enliven Therapeutics, Inc.ELVN
$0.0
N/A
(66.7%)
N/A
Median Peer Set
$0.0
14.8%
(19.3%)
7.5%
Royalty Pharma plcRPRX
$0.8
(3.8%)
(43.7%)
37.9%
argenx SEARGX
$0.0
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
$0.0
73.7%
467.1%
(35.9%)
BioMarin Pharmaceutical Inc.BMRN
$0.0
18.0%
139.3%
15.0%
BioNTech SEBNTX
$0.0
(77.4%)
(89.7%)
24.4%
Regeneron Pharmaceuticals, Inc.REGN
$0.0
8.3%
10.4%
31.1%
Summit Therapeutics Inc.SMMT
$0.0
N/A
(68.7%)
N/A
United Therapeutics CorporationUTHR
$0.0
23.6%
25.7%
41.5%
Vertex Pharmaceuticals IncorporatedVRTX
$0.0
11.7%
N/A
(4.9%)
Alnylam Pharmaceuticals, Inc.ALNY
$0.0
23.0%
(38.6%)
(12.4%)
ELVN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.6 | 0.3 |
% margin | 0.0 0.0% | 0.0 0.0% | (0.0) 0.0% | (0.1) 0.0% | (0.1) 0.0% | (0.6) 0.0% | (0.3) 0.0% |
| Operating Expenses | 8.9 | 10.7 | 24.1 | 9.3 | 24.8 | 38.8 | 83.5 |
| Research & Development Expenses (R&D) | 7.9 | 8.2 | 19.0 | 8.2 | 20.5 | 31.0 | 64.6 |
| Selling, General & Administrative Expenses (SG&A) | 1.0 | 2.4 | 5.1 | 1.1 | 4.3 | 7.8 | 19.0 |
% margin | (8.9) 0.0% | (10.7) 0.0% | (24.1) 0.0% | (9.3) 0.0% | (24.8) 0.0% | (38.8) 0.0% | (83.5) 0.0% |
| Interest Income | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | 1.1 | 12.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | 0.2 | (11.3) | (23.5) | (19.0) | (24.7) | (37.7) | (71.6) |
% effective tax rate | 0.2 100.0% | (0.8) 7.2% | 0.7 (2.8%) | (0.0) 0.2% | (0.0) 0.1% | 0.1 (0.2%) | 0.0 0.0% |
% margin | 0.0 0.0% | (11.3) 0.0% | (23.5) 0.0% | (18.9) 0.0% | (24.7) 0.0% | (37.8) 0.0% | (71.6) 0.0% |
| EPS | 0.00 | (2.62) | (5.43) | (14.14) | (3.17) | (6.03) | (2.01) |
| Diluted EPS | 0.00 | (2.62) | (5.43) | (14.14) | (3.17) | (6.03) | (2.01) |
% margin | 0.2 0.0% | (11.3) 0.0% | (23.4) 0.0% | (9.3) 0.0% | (24.6) 0.0% | (38.6) 0.0% | (81.9) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Enliven Therapeutics, Inc.'s Dividend per Share (DPS)?
As of today, Enliven Therapeutics, Inc.'s last 12-month Dividend per Share (DPS) is $0.0, based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Enliven Therapeutics, Inc.'s Dividend per Share (DPS) growth rate?
Over the last year, Enliven Therapeutics, Inc.'s Dividend per Share (DPS) growth was N/A. The average annual Dividend per Share (DPS) growth rates for Enliven Therapeutics, Inc. have been N/A over the past three years, N/A over the past five years.